Drug Interactions between Genpril and zidovudine
This report displays the potential drug interactions for the following 2 drugs:
- Genpril (ibuprofen)
- zidovudine
Interactions between your drugs
ibuprofen zidovudine
Applies to: Genpril (ibuprofen) and zidovudine
MONITOR: Limited clinical data suggest that the concomitant use of zidovudine with nonsteroidal anti-inflammatory agents may increase the risk of hematological toxicity and/or bleeding in HIV-positive patients with hemophilia. The mechanism is unknown.
MANAGEMENT: It is recommended to monitor patients for side effects and bleeding during concomitant use.
References (6)
- Sim SM, Back DJ, Breckenridge AM (1991) "The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes." Br J Clin Pharmacol, 32, p. 17-21
- Sahai J, Gallicano K, Garber G, et al. (1992) "Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus." Clin Pharmacol Ther, 52, p. 464-70
- Sahai J, Gallicano K, Conway B, et al. (1992) "Lack of pharmacokinetic interaction between naproxen (N) and zidovudine (Z)." Clin Pharmacol Ther, 51, p. 184
- Burger DM, Meenhorst PL, Koks CH, Beijnen JH (1993) "Drug interactions with zidovudine." AIDS, 7, p. 445-60
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
Drug and food interactions
ibuprofen food
Applies to: Genpril (ibuprofen)
GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.
MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.
References (1)
- (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
zidovudine food
Applies to: zidovudine
Food may have variable effects on the oral bioavailability of zidovudine. Fatty foods have been reported to decrease the rate and extent of zidovudine absorption following oral administration. In a study of 13 AIDS patients, mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of zidovudine were 2.8 and 1.4 times higher, respectively, in fasting patients than in those administered the medication with breakfast. In addition, variations in plasma zidovudine concentrations were increased when administered in the fed state. In another study of eight patients, the time to reach peak concentration (Tmax) was increased from 0.68 to 1.95 hours, and Cmax was reduced by 50% when zidovudine was administered with a liquid high-fat meal relative to fasting. Protein meals can also delay the absorption and reduce the Cmax of zidovudine, although the extent of absorption is not significantly affected. The clinical significance of these alterations, if any, is unknown. The product labeling states that zidovudine may be taken with or without food.
References (4)
- Lotterer E, Ruhnke M, Trautman M, et al. (1991) "Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal." Eur J Clin Pharmacol, 40, p. 305-8
- Unadkat JD, Collier AC, Crosby SS, et al. (1990) "Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal." AIDS, 4, p. 229-32
- (2001) "Product Information. Retrovir (zidovudine)." Glaxo Wellcome
- Sahai J, Gallicano K, Garber G, et al. (1992) "The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients." Br J Clin Pharmacol, 33, p. 657-60
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.